FURTHER INSIGHTS INTO PALEOINDIAN USE OF THE POWARS II RED OCHER QUARRY (48PL330), WYOMING
Sign Up to like & getrecommendations! Published in 2018 at "American Antiquity"
DOI: 10.1017/aaq.2018.11
Abstract: We report major new insights from recent research at the Powars II Paleoindian red ocher quarry (48PL330). We salvaged more than 7,000 artifacts from Powars II between 2014 and 2016 by screening redeposited sediment from… read more here.
Keywords: red ocher; ocher quarry; clovis; quarry 48pl330 ... See more keywords
P142 Results of the 3rd interim analysis of C-Patrol: a non-interventional study on olaparib in german routine clinical practice
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.204
Abstract: Introduction/Background Olaparib (50 mg hard capsules, HC) was the 1st PARPi approved in the EU in 12/2014 as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) ovarian cancer (PSR-OC) who are… read more here.
Keywords: 3rd interim; interim analysis; clovis; roche ... See more keywords
Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.28
Abstract: Introduction/Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo in all patient populations, regardless of biomarker status (Coleman et al. Lancet. 2017;390:1949–61). This subgroup analysis examined the effect of the stratification… read more here.
Keywords: pfi; astrazeneca; clovis; clovis astrazeneca ... See more keywords